Drug Profile
UCART 19
Alternative Names: CD19CAR/RQR8+_TCRαβ–_T-cells; S-68587; S-95023; UCART19Latest Information Update: 28 Oct 2023
Price :
$50
*
At a glance
- Originator Cellectis
- Developer Cellectis; Pfizer; Servier
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Haematological malignancies
- Phase I Lymphoid leukaemia
- No development reported Chronic lymphocytic leukaemia; Precursor B-cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for phase-I development in Precursor-B-cell-lymphoblastic-leukaemia-lymphoma(In adolescents, In children, In infants, Second-line therapy or greater) in Belgium (IV, Infusion)
- 28 Oct 2023 No recent reports of development identified for phase-I development in Precursor-B-cell-lymphoblastic-leukaemia-lymphoma(In adolescents, In children, In infants, Second-line therapy or greater) in France (IV, Infusion)
- 28 Oct 2023 No recent reports of development identified for phase-I development in Precursor-B-cell-lymphoblastic-leukaemia-lymphoma(In adolescents, In children, In infants, Second-line therapy or greater) in Spain (IV, Infusion)